within Pharmacolibrary.Drugs.C_CardiovascularSystem.C02C_AntiadrenergicAgentsPeripherallyActing.C02CA06_Urapidil;

model Urapidil_1
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 9.216666666666666e-06,
    adminDuration = 600,
    adminMass = 60 / 1000000,
    adminCount = 1,
    Vd = 0.00087,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.00109,
    k12 = 0.00010616666666666667,
    k21 = 0.00010616666666666667);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Urapidil_1</td></tr><tr><td>ATC code:</td><td>C02CA06_1</td></tr><td>route:</td><td>orally</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>60</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.87</td><td>L</td></tr>
    <tr><td>clearance:</td><td>7.9</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Urapidil is an antihypertensive agent acting as an alpha-1 adrenergic receptor antagonist and 5-HT1A receptor agonist. It is mainly used for the treatment of acute and chronic hypertension. Urapidil is not approved by the US FDA but is used in several European countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters of urapidil after oral administration in healthy adult male volunteers.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C02CA06_1 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Urapidil_1;
